Addiction Treatment
Addiction Treatment RSS Feed RSS

A Possible Option in Opioid-Related Harm Reduction

August 6, 2020
Greg Sazima, MD
Greg Sazima, MD Dr. Sazima has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Medications are the mainstay of treatment for opioid use disorder (OUD), but what if patients decline buprenorphine, injectable naltrexone, and methadone? In this randomized trial, authors compared hydromorphone (Dilaudid) with diacetylmorphine (the active ingredient in heroin) among patients who reported injecting heroin.
Read More

Efficacy and Acceptability of Varenicline for Alcohol Use Disorder

August 6, 2020
Richard Moldawsky, MD
Richard Moldawsky, MD Dr. Moldawsky has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Smoking tobacco and drinking alcohol have reciprocal influences on each other. In this meta-analysis of nine randomized studies, the authors appraise the evidence for varenicline use for alcohol use disorder specifically.
Read More

Note From the Editor-in-Chief

June 10, 2020
Benjamin Oldfield
Benjamin Oldfield Editor-in-Chief of CATR. Clinical Instructor in Medicine and Pediatrics at Yale School of Medicine; Chief Medical Officer at Fair Haven Community Health Care, CT. Dr. Oldfield has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The expansion of telemedicine—which health systems had been slow to adopt and payers had been reluctant to reimburse for years—has zoomed ahead in recent weeks. Sure, it’s not perfect: The video connections can be finicky, and learning new digital platforms can pose challenges for both patients and providers. But with...
Read More

The “Z-Drugs”: Safety Issues and Misuse Potential

June 10, 2020
Rehan Aziz, MD.
Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Once heralded for their relative safety compared to benzodiazepines, the “Z-drugs” are now known to be one of the most common causes of adverse drug events. Here we review the risks of Z-drugs and highlight updated dosing recommendations for zolpidem.
Read More
EXPERT Q&A

Gabapentin Misuse and Diversion

June 10, 2020
Rachel Vickers-Smith, PhD, MPH

Rachel Vickers-Smith, PhD, MPH
Assistant Professor at University of Louisville, KY. Dr. Vickers-Smith has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Clinicians are increasingly turning to gabapentinoids as non-opioid alternatives for pain treatment. Yet we may be inadvertently introducing new risks in so doing. Dr. Vickers-Smith reviews current epidemiology of gabapentinoid use and offers some clues regarding how to turn the tide on gabapentin misuse.
Read More

SAMHSA Relaxes Regulations on Methadone and Buprenorphine During COVID-19 Emergency

June 10, 2020
Benjamin Oldfield
Benjamin Oldfield Editor-in-Chief of CATR. Clinical Instructor in Medicine and Pediatrics at Yale School of Medicine; Chief Medical Officer at Fair Haven Community Health Care, CT. Dr. Oldfield has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In the context of a pandemic, how can and should our practices change to continue to meet the needs of patients with opioid use disorder? We summarize recent changes to the regulations surrounding medications for opioid use disorder: buprenorphine and methadone.
Read More

Muscle Relaxants: Sedatives Often Under the Radar

June 10, 2020
Michael Weaver, MD, FASAM.
Michael Weaver, MD, FASAM. Professor and medical director at the Center for Neurobehavioral Research on Addictions at the University of Texas Medical School. Author of Addiction Treatment (Carlat Publishing, 2017). Dr. Weaver has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Muscle relaxants encompass medications with different mechanisms of action—many of which have been used for decades. Yet most are sedating, can have significant side effects, and can interact with opioids and other substances to worsen CNS and respiratory depression.
Read More
EXPERT Q&A

Benzodiazepines: Old Medicines, New Concerns

June 10, 2020
Kenneth Morford, MD

Kenneth Morford, MD
Assistant Professor and Program Director, Collaborative Behavioral Health & Addiction Medicine in Primary Care (CHAMP) at Yale School of Medicine. Dr. Morford has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Benzodiazepine use is on the rise, and is implicated with a significant portion of opioid-related overdose deaths. Dr. Morford gives the latest on benzodiazepine prevalence and suggests strategies to employ in addiction treatment settings when working with patients who use benzodiazepines.
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.